Philadelphia Pharmaceuticals Co.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: JO4121911013
JOD
1.55
-0.04 (-2.52%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
Dar Al Dawa Development & Investment Co. Ltd.
Philadelphia Pharmaceuticals Co.
Hayat Pharmaceutical Industries Co. Ltd.

Why is Philadelphia Pharmaceuticals Co. ?

1
Flat results in Dec 25
  • OPERATING CASH FLOW(Y) Lowest at JOD 0.64 MM
  • ROCE(HY) Lowest at 0%
  • DIVIDEND PAYOUT RATIO(Y) Lowest at 154.19%
2
With ROE of 7.02%, it has a attractive valuation with a 0.00 Price to Book Value
  • Over the past year, while the stock has generated a return of 7.64%, its profits have risen by 9%
3
Underperformed the market in the last 1 year
  • The stock has generated a return of 7.64% in the last 1 year, much lower than market (Jordan General Index) returns of 41.27%
stock-recommendationReal-Time Research Report

Verdict Report

How much should you hold?

  1. Overall Portfolio exposure to Philadelphia Pharmaceuticals Co. should be less than 10%
  2. Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Philadelphia Pharmaceuticals Co. for you?

Medium Risk, Low Return

Absolute
Risk Adjusted
Volatility
Philadelphia Pharmaceuticals Co.
7.64%
0.34
20.22%
Jordan General Index
41.27%
4.23
9.76%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
3.66%
EBIT Growth (5y)
16.11%
EBIT to Interest (avg)
1.03
Debt to EBITDA (avg)
0.32
Net Debt to Equity (avg)
0.05
Sales to Capital Employed (avg)
0.59
Tax Ratio
21.07%
Dividend Payout Ratio
52.24%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
7.95%
ROE (avg)
4.90%
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
Industry P/E
Price to Book Value
NA
EV to EBIT
0.63
EV to EBITDA
0.50
EV to Capital Employed
0.07
EV to Sales
0.10
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
10.62%
ROE (Latest)
7.02%
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
Bearish
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
No Trend
Bearish
OBV
No Trend
Mildly Bullish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

5What is working for the Company
RAW MATERIAL COST(Y)

Fallen by -15.01% (YoY

OPERATING PROFIT(Q)

Highest at JOD 0.62 MM

OPERATING PROFIT MARGIN(Q)

Highest at 26.76 %

PRE-TAX PROFIT(Q)

Highest at JOD 0.43 MM

NET PROFIT(Q)

Highest at JOD 0.34 MM

-9What is not working for the Company
OPERATING CASH FLOW(Y)

Lowest at JOD 0.64 MM

ROCE(HY)

Lowest at 0%

DIVIDEND PAYOUT RATIO(Y)

Lowest at 154.19%

CASH AND EQV(HY)

Lowest at JOD 1.6 MM

INVENTORY TURNOVER RATIO(HY)

Lowest at 0 times

DEBTORS TURNOVER RATIO(HY)

Lowest at 0 times

EPS(Q)

Lowest at JOD 0

Here's what is working for Philadelphia Pharmaceuticals Co.

Operating Profit
Highest at JOD 0.62 MM
in the last five periods
MOJO Watch
Near term Operating Profit trend is positive

Operating Profit (JOD MM)

Operating Profit Margin
Highest at 26.76 %
in the last five periods
MOJO Watch
Company's profit margin has improved

Operating Profit to Sales

Pre-Tax Profit
Highest at JOD 0.43 MM
in the last five periods
MOJO Watch
Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (JOD MM)

Net Profit
Highest at JOD 0.34 MM
in the last five periods
MOJO Watch
Near term Net Profit trend is positive

Net Profit (JOD MM)

Raw Material Cost
Fallen by -15.01% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Philadelphia Pharmaceuticals Co.

Operating Cash Flow
Lowest at JOD 0.64 MM
in the last three years
MOJO Watch
The company's cash revenues from business operations are falling

Operating Cash Flows (JOD MM)

EPS
Lowest at JOD 0
in the last five periods
MOJO Watch
Declining profitability; company has created lower earnings for shareholders

EPS (JOD)

Cash and Eqv
Lowest at JOD 1.6 MM
in the last six Semi-Annual periods
MOJO Watch
Short Term liquidity is deteriorating

Cash and Cash Equivalents

Inventory Turnover Ratio
Lowest at 0 times
in the last five Semi-Annual periods
MOJO Watch
Company's pace of selling inventory has slowed

Inventory Turnover Ratio

Debtors Turnover Ratio
Lowest at 0 times
in the last five Semi-Annual periods
MOJO Watch
Company's pace of selling Debtors has slowed

Debtors Turnover Ratio

Dividend Payout Ratio
Lowest at 154.19%
in the last five years
MOJO Watch
Company is distributing lower proportion of profits generated as dividend

DPR (%)